Slide 1: Q4 2021 Results Presentation
Q4 2021 Results Presentation Dietmar Siemssen, CEO Bernd Metzner, CFO Duesseldorf, February 17, 2022
Slide 2: Disclaimer
Disclaimer − This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development
Slide 3: Taking Growth to the Next Level
Taking Growth to the Next Level CEO Dietmar Siemssen
Slide 4: Transforming Gerresheimer into a growth company
Transforming Gerresheimer into a growth company as innovation leader, solution provider and system integrator. 201 5
Slide 5: Delivering High Growth – Profitably and Sustainably
Delivering High Growth – Profitably and Sustainably formula G: Significant Operational and Financial Progress ▪ Driven by our mission: innovate and deliver for a better life – every day ▪ Already now, we are the leading partner for pharma, biotech, healthcare and beauty customers globally ▪ Successf
Slide 6: Increased Dynamic for Organic Revenue Growth
Increased Dynamic for Organic Revenue Growth Key Take-Aways FY 2021: Strong Performance High Single-Digit Growth: Boosting Revenue guidance Org. revenue growth: High Value Solutions: surpassed – taking Adj. EBITDA (EURm): +7.6% core 1 >30% yoy growth to a new level 324m core1 (FXN) +7.4% group Adj.
Slide 7: Growth Accelerated: Driving the Transformation
Growth Accelerated: Driving the Transformation Strategic Focus in 2021 Growth: formula G: Cost Inflation: Accelerated Role Out Resilience of Progressing business model proven Innovation: Capex: Sustainability: Focus on own IP & Growth investments Ambitious targets strategic focused on strong and str
Slide 8: Accelerating our Growth
Accelerating our Growth Building on the Key Achievements of 2021 2021 2022 and beyond… Investing in the growth areas of tomorrow Key achievements with a sharp focus on innovation and developing our own IP Record order Accelerating Expanding intake for 1. Leading market positions in attractive, Injec
Slide 9: The World Leader in Vials
The World Leader in Vials Growth: Partner for Pharma and Biotech - Worldwide Growing demand for injectables: Increase global capacity for vials Expand Wertheim plant: one example of the continuous Our targets: implementation of formula G - Highest quality and availability Increase capacity in - Maxi
Slide 10: Enhance our Offering with High Value Solutions
Enhance our Offering with High Value Solutions Innovate: Increase Focus on Own IP and R&D Gerresheimer is a growth company as innovation leader, solution provider and system integrator Continue to innovate: own products with own IP Strategic partnerships and collaborations High Value Solutions as ke
Slide 11: Strong Partnerships & Own IP Prove Innovation Power
Strong Partnerships & Own IP Prove Innovation Power Innovate: Leveraging our Vision of Innovating for a Better Life BIOLOGICS Customer G-Injector Continue to innovate: − Strong partnership Strategic partnerships own products − Enhancing existing with a well-known and collaborations product portfolio
Slide 12: Advanced Technologies: Nucleus for Smart Devices
Advanced Technologies: Nucleus for Smart Devices Innovate: Examples of Advanced Technology Products and Projects GAT is an integral part of our growth strategy and contributes to our vision „innovating for a better life“ Parkinson Wearable pump Pump On-Body drug delivery device – Patch pump together
Slide 13: Strong Q4 & FY 2021
Strong Q4 & FY 2021 CFO Dr. Bernd Metzner
Slide 14: Q4 2021: Strong Revenue Growth
Q4 2021: Strong Revenue Growth Operational View on KPIs Revenues Adj. EBITDA Adj. EPS (in EUR m) (in EUR m) (in EUR) organic growth yoy -3.3% organic growth yoy organic growth 9.3% core business: 2.3% core business: yoy: Adj. EBITDA margin core 23.1% 436 (FXN): 403 100 1.32 1.31 95 433 401 100 96 1.
Slide 15: Strong Positions Provide Pricing Power
Strong Positions Provide Pricing Power Q4 2021 Adj. EBITDA Margin Reconciliation in Gx Core (in %) 0.0 26.1 26.1 ~2.4 23.1 0.6 Q4 2021 Q4 Subsequent Q4 2021 Q4 2020 FX-neutral Quarters FX-neutral FX-neutral Pro-forma Pass-Through Effects: Temporary Effects: 2.5-3% on sales Q4 impact of around EUR 10
Slide 16: Strong Q4 Sales Performance in Core Business
Strong Q4 Sales Performance in Core Business Q4 2021: Divisional Performance and Highlights Organic yoy & margin In EUR m Revenues Adj. EBITDA Strong organic revenue growth +9.9% -7.5% — Strong organic revenue growth in all business units 241 73 — PPP incl. Centor revenue benefitting from pass-throu
Slide 17: Strong Free Cash Flow Contribution
Strong Free Cash Flow Contribution Cash Flow and Financial Debt Q4 2021 Q4 2020 Change In EUR m Comments Adjusted EBITDA 95.4 99.9 -4.5 EUR ~ -1m negative FX effects Change in net working capital 63.6 44.8 18.8 Further improvement of net working capital Net interest paid -11.8 -11.1 -0.7 Net taxes p
Slide 18: Reconciliation FY 2021
Reconciliation FY 2021 Reported and Adjusted Financials FY 2021 Org. FY 2020 growth Comments Adjust- YoY1 In EUR m Reported Adjusted Adjusted ment Adjusted Revenues 1,498.0 1,498.0 1,418.8 7.4% Core +7.6%: beating high end of guidance range EBITDA 287.4 18.9 306.3 310.1 1.8% Core FXN: 324m EUR meeti
Slide 19: Focused on Driving Shareholder Value
Focused on Driving Shareholder Value Strong Start to 2022 as we Continue to Allocate Capital to Optimise Returns Dividend proposal: 1.25 EUR per share – again at the higher end of our pay-out ratio of 20-30% Strong start to FY 2022: with double-digit revenue and adj. EBITDA growth in Q1 Leverage bus
Slide 20: Outlook
Outlook CEO Dietmar Siemssen
Slide 21: Transforming Gerresheimer into a growth company
Transforming Gerresheimer into a growth company as innovation leader, solution provider and system integrator. 2022 201 5
Slide 22: High Single-Digit Organic Revenue Growth in 2022
High Single-Digit Organic Revenue Growth in 2022 Key Contributors to Growth: We Will Deliver Returns on investment in Enhanced de-risked regional sales expansion Serving beauty activities customers with esp. China high-end (pharma) solutions Realising benefits of prior years investment in innovation
Slide 23: Delivering Sustainably Higher Profitable Growth
Delivering Sustainably Higher Profitable Growth Continued Acceleration in 2022; Raising Medium-term EBITDA Guidance Group level guidance (FXN) focused on three key drivers of shareholder value Adj. EBITDA/ Revenue Adj. EPS Margin High High High FY 2022 single-digit single-digit single-digit growth g
Slide 24: Commitment and Delivery
Commitment and Delivery Focus for 2022 What we achieved in FY 2021: What to expect in 2022: Accelerate: Delivered according to plan Another record year driven by higher value products and solutions Execute: Filled the pipeline – emphasis on high value solutions Translate strong order backlog into pr
Slide 25: Appendix
Appendix 25 02/17/2022 Q4 2021 Earnings Presentation
Slide 26: Financial Calendar
Financial Calendar Publication 1st Annual General Publication 2nd Publication 3rd Quarter Results 2022 Meeting Quarter Results 2022 Quarter Results 2022 April June July October 07, 2022 08, 2022 13, 2022 12, 2022 26 02/17/2022 Q4 2021 Earnings Presentation
Slide 27: Q4 Revenue & Organic Growth Reconciliation
Q4 Revenue & Organic Growth Reconciliation (1 of 4) in EUR m organic growth +7.8% 3.5 436.1 -4.2 432.6 15.3 -1.5 21.7 402.8 401.3 -1.5 +8.6% +9.9% Revenue FX Revenue Q4 P&D PPG GAT HQ, Cons. Revenue Q4 FX Revenue Q4 2020 2020 (FXN) 2021 (FXN) Q4 2021 +9.3% 3.5 437.6 434.1 15.3 21.7 398.7 397.1 -1.5
Slide 28: YTD Revenue & Organic Growth Reconciliation
YTD Revenue & Organic Growth Reconciliation (2 of 4) in EUR m organic growth +7.4% 1,496.6 1.4 1,498.0 -1.5 -0.2 54.8 1,418.8 50.3 -25.6 1,393.2 +8.7% +6.6% Revenue FX Revenue FY P&D PPG GAT HQ, Cons. Revenue FY FX Revenue FY 2020 2020 (FXN) 2021 (FXN) FY 2021 +7.6% 1,495.2 1.4 1,496.6 54.8 1,415.7
Slide 29: Q4 EBITDA & Organic Growth Reconciliation
Q4 EBITDA & Organic Growth Reconciliation (3 of 4) in EUR m organic growth & margin -4.1% 99.9 99.6 -0.3 -0.6 -5.4 4.7 -2.7 95.5 95.4 -0.1 -7.5% +12.3% +24.8% +22.1% Adj. EBITDA FX Adj. P&D PPG GAT HQ, Cons. Adj. FX Adj. EBITDA Q4 2020 EBITDA Q4 EBITDA Q4 Q4 2021 2020 (FXN) 2021 (FXN) -3.3% 104.0 10
Slide 30: YTD EBITDA & Organic Growth Reconciliation
YTD EBITDA & Organic Growth Reconciliation (4 of 4) in EUR m organic growth & margin +1.8% 310.1 309.5 -0.2 -0.4 -6.1 306.3 304.1 8.5 -3.2 -2.4 -1.2% +6.3% +21.8% +20.7% Adj. EBITDA FX Adj. P&D PPG GAT HQ, Cons. Adj. FX Adj. EBITDA FY 2020 EBITDA FY EBITDA FY FY 2021 2020 (FXN) 2021 (FXN) +1.8% 324.
Slide 31: Reconciliation Q4 2021
Reconciliation Q4 2021 Reported and Adjusted Financials on Group Level Q4 2021 Q4 2020 Organic growth YoY1 In EUR m Reported Adjustment Adjusted Adjusted Adjusted Revenues 436.1 436.1 402.8 7.8% EBITDA 91.0 4.4 95.4 99.9 -4.1% Depreciation & -39.5 9.5 -30.0 -31.7 Amortization EBIT 51.5 13.9 65.4 68.
Slide 32: Financial Headroom
Financial Headroom Net Financial Debt & Adjusted EBITDA Leverage Net financial debt according to credit agreement in force Maturity Profile In EUR m Net financial debt (In EUR m)1 961 Promissory loans 923 RCF 3.2 3.0 Adj. EBITDA leverage (x) 551 Nov-20 Nov-21 75 In EUR m Q4 2021 Q4 2020 Drawn portio
Slide 33: serresheimer
serresheimer innovating for a better life